Categories
· Health/Science
· Business (Tobacco)
· Cessation
· Nicotine
Organizations
· RJR
|
Jump to full article: Business Journal of the Greater Triad Area, 2008-05-05
Intro: Targacept has announced a leading compound in its effort to develop a smoking-cessation treatment program, the company has announced.
The milestone for the Winston-Salem-based biotech, which was spun out of research into how nicotine interacts with the brain begun by R.J. Reynolds Tobacco Co., triggers a $500,000 payment from Targacept's development partner GlaxoSmithKline.
Targacept said in an announcement that the focus of its anti-smoking efforts is on counteracting the addictive nature of nicotine by manipulating "neuronal nicotinic receptors" or NNRs, which are proteins in the nervous system that control the levels of key chemical messengers.
Jump to full article » |